Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P02794 (ferritin)
 17,525 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

It is well known that macrophages are the principle cells responsible for removal of senescent erythrocytes from circulation and are the major storage cell for body iron. Monitoring stored iron in patients with anemia secondary to renal failure and chronic hemodialysis is an important parameter used for gauging supplementing these patients with iron. We have proven that blood monocyte ferritin unlike serum ferritin reflects adequately bone marrow iron stores and thus replaces an undesirable procedure in such patients namely bone marrow punctures.
 ...
PMID:Monocyte ferritin as a possible index of bone marrow iron stores in patients on chronic hemodialysis. 229 47

Fourteen nondialyzed patients with chronic renal insufficiency (serum creatinine 265 to 972 mumol/L [3.0 to 11.0 mg/dL]) and severe anemia (hematocrit less than 30%) were randomized to receive either recombinant human erythropoietin (r-HuEPO) or a placebo subcutaneously thrice weekly for 12 weeks or until reaching a hematocrit of 38% to 40%. Anemia was significantly ameliorated in the treated patients. No acceleration in the progression of renal failure (1/serum creatinine v time) or change in serum potassium was noted for either the placebo or treated group over the 12-week period. Six of seven treated patients had a significant decrease in serum ferritin and percent transferrin saturation (plasma iron/total iron-binding capacity). This resulted in functional iron deficiency and the requirement for iron supplementation. The average systolic and diastolic blood pressure did not differ significantly between the two groups of patients during the study. Quality of life was improved in all r-HuEPO-treated patients but not in those in the placebo group. This study demonstrates the safety and efficacy of r-HuEPO in the correction of anemia in predialysis patients without adverse effects on renal function over a 12-week period. Improved patient well-being as a result of the correction of anemia resulted in one patient refusing appropriate initiation of dialysis therapy.
 ...
PMID:The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial. 268 5

We treated three children with renal failure and chronic iron overload with intraperitoneal deferoxamine therapy. Each child had an elevated serum ferritin level, a dense liver as measured by computerized tomography (Hounsfield Units) and one had dialysis related porphyria cutanea tarda. Deferoxamine therapy (10 to 17.5 mg/kg) was given in the overnight exchange for three to six months. Prior to therapy, iron was not detected in the dialysate; during the course of therapy, daily dialysate iron removal averaged 5652 micrograms, 2241 micrograms and 4028 micrograms in the three children. The serum ferritin level fell during the course of therapy in two children who were estimated to be in negative iron balance, and was unchanged in the third who was estimated to be in positive iron balance due to frequent transfusions. In 10 children with chronic renal failure, there was a linear correlation (r = 0.855; P less than 0.01) between the serum ferritin and the liver density, suggesting that an increased serum ferritin correlates with hepatic iron content. Interestingly, in each of the three children who received deferoxamine therapy, the liver density increased during therapy regardless of the estimated iron balance and the change in the serum ferritin level. We conclude that intraperitoneal deferoxamine therapy results in substantial iron losses in peritoneal dialysate, can result in negative iron balance but, in this study, did not result in lower liver iron content as measured by density on computerized tomography scan.
 ...
PMID:Intraperitoneal deferoxamine therapy for iron overload in children undergoing CAPD. 277 Jan 13

Recent studies have suggested a role for thromboxane in the progression of renal disease. The current study evaluated the role of this arachidonic acid metabolite in a model of renal disease which bears many biologic similarities to that in the kidneys of patients with chronic progressive renal failure. The model is that induced by ferritin-anti-ferritin immune complex nephritis in Dahl-salt sensitive rats rendered hypertensive by a high salt intake. Rats with this model of renal disease were chronically given a thromboxane synthetase antagonist OKY-046 or a placebo treatment from 16 to 29 weeks of age. Sequential observations of serum creatinine and 24-hour urinary protein excretion showed an ameliorating effect of OKY-046 on these renal parameters. Histologic examination of the kidneys also showed significantly less glomerular sclerosis in OKY-046 treated animals. The efficacy of OKY-046 was monitored by measurements of serum TXB2 levels and of glomerular production of TXB2 (and other prostaglandins); amounts of TXB2 were significantly reduced in the OKY-046 group. It is concluded that blockade of thromboxane generation has been successful in ameliorating the functional and structural lesions in this model of renal disease, providing further support to the thesis that thromboxane is an important mediator in events leading to eventual chronic renal failure and sclerosis.
 ...
PMID:A thromboxane synthetase antagonist ameliorates progressive renal disease of Dahl-S rats. 296 73

Hemorrhage values and the amount of iron entering the body with drugs and blood transfusions were determined in 107 patients with the terminal CRF stage. Of them 59 received regular hemodialyses. The level of serum iron and ferritin as well as iron reserves in the body were investigated at the start and end of the study. In the end a histochemical study of the content of hemosiderin in the bone marrow, liver and spleen was performed. A close interrelationship of iron reserves determined with a modified desferal test and the level of serum ferritin (r = 0.94) was established. The highest iron reserves were revealed in the patients receiving blood transfusions and parenteral iron drugs. Criteria for the assessment of iron reserves in patients with renal failure were determined by means of the modified desferal test and investigation of serum ferritin. Normal ferritin reserves in such patients corresponded to serum ferritin values within the range of 50-400 micrograms/l and indices of the modified desferal test ranging from 0.4 to 2.0/0.5 g of desferal. Of a degree of hemosiderosis one could judge on the basis of a histochemical investigation of tissue hemosiderin only. Iron drugs per os were proposed for the prevention of disorders of iron balance in patients with renal failure.
 ...
PMID:[Iron reserves in patients with chronic renal insufficiency]. 368 52

The effects of biological (age, sex, weight) and pathological factors on plasma ferritin concentrations were documented in 776 unselected elderly patients aged 80.9 +/- 9.7 yr. A marked shift towards high values (159 +/- 142 micrograms/l) was observed in this elderly population together with the persistence of the well-known sex-related difference in ferritin levels (higher levels in men). Twenty-five percent of the population had high levels of ferritin (greater than or equal to 220 micrograms/l) but 75% of these high values (i.e. 18.5% of the population) could be readily explained by their known association with a particular pathology (inflammatory syndrome, renal failure, cardiovascular diseases, alcoholism). Only 6% of the population had unexplained high ferritin concentrations. Therefore, our data strongly suggest that the repeatedly reported increase of ferritin in the aged population is merely related to an age-associated pathology and may not be a normal physiological event occurring during the process of aging.
 ...
PMID:Plasma ferritin in old age. Influence of biological and pathological factors in a large elderly population. 402 33

Serum ferritin and bone marrow haemosiderin iron was studied in 50 non-dialysis patients with chronic renal failure, and in 53 healthy subjects. S-ferritin was correlated to marrow iron both in patients with renal failure and in healthy subjects (P less than 0.001). Geometric-mean S-ferritin in patients with 0- (1+) marrow iron was 33 micrograms/l, 1+ marrow iron 166 micrograms/l, and 2+ marrow iron 519 micrograms/l. Healthy subjects with 0- (1+) marrow iron had a mean S-ferritin of 16 micrograms/l and those with 1+ marrow iron a value of 65 micrograms/l. S-ferritin levels were higher in patients than in healthy subjects at all marrow iron grades (P less than 0.001). Healthy subjects with S-ferritin less than 15 micrograms/l had absent or reduced marrow iron, while those with S-ferritin greater than 30 micrograms/l had normal marrow iron. Using a critical S-ferritin value of less than or equal to 20 micrograms/l, the diagnostic efficiency in terms of diagnosing absent or reduced marrow iron was 0.90 (PV pos = 0.85, Pv neg = 0.91). In patients with renal failure S-ferritin less than 60 micrograms/l indicated absent or reduced marrow iron, while values greater than 80 micrograms/l were associated with normal marrow iron. The diagnostic efficiency of S-ferritin using a critical value of less than or equal to 60 micrograms/l was 0.94 (PV pos = 0.93, PV neg = 0.97). S-ferritin is a useful indicator of marrow iron stores in patients with chronic renal failure.
 ...
PMID:Serum ferritin in non-dialysis patients with chronic renal failure: relation to bone marrow iron stores. 685 49

The changes were compared of the iron curve in children with chronic renal failure and with terminal renal failure after oral loading dose of ferrous sulphate. Flat curve of absorption was found in both groups of patients with increased stores of systemic iron and high values of transferrin saturation index (TSI). Steep iron curve and very good absorption were found in all children with decreased serum level of ferritin and decreased TSI. The curves of iron absorption at serum ferritin level 250-500 ng/ml pointed to impaired absorption and depended on the initial TSI value and initial iron level in the serum. No significant differences were found in the shape of iron curve depending on dialysing methods. Studying of the iron curve and values of TSI in certain patients makes easier the decision of administration of treatment with oral iron preparations even with increased values of TSI and ferritin in the serum.
 ...
PMID:[Assessment of iron absorption in children with chronic renal insufficiency]. 757 14

The purpose of this study was to evaluate the sensitivity and specificity of laboratory methods in the diagnosis of posterythropoietin-era, iron-deficient, chronic renal failure patients. The patient population comprised 25 anemic (hemoglobin < 11 g/dL) patients with creatinine greater than 3 mg/dL; 20 were dialysis patients, two were transplant patients, and three patients had renal failure from other causes. Criteria for study inclusion were as follows: bone marrow iron was the reference standard and was graded 0 to +4, ranging from absent to diffuse homogeneous iron staining; serum ferritin concentration and serum transferrin saturation were tested in terms of sensitivity and specificity. The reference standard indicated that iron deficiency existed in 40% of patients. Neither serum ferritin nor transferrin saturation were completely adequate diagnostic tools. Serum ferritin levels less than 200 ng/dL were 100% specific for the diagnosis but only 41% sensitive. Transferrin saturation of less than 20% was 88% sensitive, but only 63% specific. By excluding patients with hypoproteinemia (transferrin values of < 150 mg/dL), the sensitivity of the test increased to 100% and the specificity to 80%. We conclude that transferrin saturation is an adequate screening tool in anemic chronic renal failure patients, provided that hypoproteinemia is not present. By determining both the serum ferritin concentration and the transferrin saturation, a high sensitivity and specificity can be achieved, even in patients with hypoproteinemia. Furthermore, we believe that on this basis, iron therapy in patients with renal insufficiency can be improved.
 ...
PMID:Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. 862 43

All adult patients from 13 dialysis centres were prospectively followed up for 6 months in an attempt to appraise the current risk factors for bacterial infections in stable chronically haemodialysed patients. Parameters recorded as potential risk factors for BI were age, gender, cause of renal failure, time elapsed since the start of dialysis, history of transplantation, recent surgical procedure, previous bacterial infection, current immunosuppressive or erythropoietin therapy, type of angioaccess device, and serum ferritin level. Six hundred and seven patients (mean age 56.5 years, range 18-85) were enrolled in the study. Mean time elapsed since the start of dialysis was 4.7 years. One hundred and eighteen patients had developed at least one bacterial infection during the study period whereas 489 had remained free of bacterial infection at the end of the follow-up. In multivariate analysis three parameters were found to be significant and independent risk factors for bacterial infection: previous history of bacterial infection (at least one versus no previous episode), type of angioaccess device (catheter versus native fistula), and elevated serum ferritin level (greater versus lower than 500 micrograms/l). These results support the evidence that impaired host defences in chronic haemodialysis patients may be secondary to the dialysis procedure and suggest that the incidence of bacterial infection in these patients may be further reduced by appropriate supportive therapy.
 ...
PMID:Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey. 779 34


<< Previous 1 2 3 4 5 6 7 8 Next >>